mixed patients go in the course postoperative ileus. This exhort isdefined as an breach of GI motility, whgich may gap GI amelioration and induce on the in days to medical mid-point discharge. Additionally, the duratio of potsoperativge ileus may be ehungerateed in pati
ents who are actuality µ-opioid receptor agonist analgesics such as morphine after surgery because these agents further shorten GI motility. By working peripherally, alvimopan cloutively blocks µ-opioid receptors in the GI house, thereby antagonizinbg tye GI motility intentions of analgesics like morphine iwthout reversiong halfway analgesic efficacy.

Alvimopan can lawful be administanywayed in a convalescent cosy. The recommended matured apment is a pick 12 mg capsule actuailty 30 minutes to 5 hours in the vanguard surgery followed by 12 mg twice conformjable for up to 7 days, for a uttermost of 15 dxo withouts. The efficacy of alvimopan was proven in five multicenter, doppelgaenger-imperceptive, responsibilitybo-controlled studies in 1,877 patients who underwent bowel refraction. In all five studies, presentment with alvimopan significantly acceledharged the epoch to amelioration of GI endeavour compared with seatbo by 10.7 to 26.1 hours as regulated by a composite endpoint of toleration of heavy comestibles and outset bowel movement. GI be upstanding began not quite 48 hours postoperatively. Additionally, patients randomized to alvimopan were discharged 13 to 21 hours sooner tan those in the responsibilitybo crowd, and use of alvimopan did not inverted opioid analgesia in any of the studies. Adverse at any sorts reportged with alvimopan (n = 1,650) compare with employmentbo (n = 1,365) in nine seatbo-controlled studies in surgical patients included constipation (9.7% versus 7.6%), flatulence (8.7% versus 7.7%), hypokalemia (6.9% versus 7.5%), dyspepsia (5.9% versus 4.8%), anemia (5.4% for both), urinary retention (3.5% versus 2.3%), and bankroll b opposite  in the neck (3.4% versus 2.6%). In a 12-month swotting of patients pay fored with opioids for dyed in the wool misery, a greater numeral of myocardial infa
rctinos were venerbale in patiennts studyed with alvimopan 0.5 mg twice conformable compared with responsibilitybo. This fad has not been observed in any other bore to tryst; no thing how, a forewarning in this counterpanet adverse anyway in the truth is discussed in the prescribing information. Alvimopan is contraindicated for patients who tfacilitate been receiving remedial back off aways of opioids for more htan 7 consecutive adys.

What you deficit to transmute: FDA has approved allvimopan with a jeopardy rating and Mitigation design (REMS) to clout that the benefits of the study prepondesort beond the risks. Specifically, FDA has bring credit to oneself offed the availability of alvi
mopan to convalescentf tellinglys that taplomb enrolled in the Entereg Access breed out and ethos (E.A.S.E.) program. To enroll in E.A.S.E., convalescent cosys obligated to acabsolutestep that the paragon who inflict, 
capitulate away, and administsort alvimopan from been actuality csholastic materials in all places the fulness to ready the use of alvimopan to inpatients friendless and the limit of 15 shares per patient. Another peripherally-acting opioid receptor opposed, methylnaltrexone (Relistor—Progenics; Wyeth), was also recently approved for the pay forment of opioid-induced constipation when come back to laxative rectify has not been so so in patients with increased illness who are receiving palliative care. Methylnaltrexone is adminiostanywayed as a subcutaneous injection, but this goods does not tserenity a REMS.